<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814175</url>
  </required_header>
  <id_info>
    <org_study_id>M14-496</org_study_id>
    <secondary_id>2016-000191-21</secondary_id>
    <nct_id>NCT02814175</nct_id>
  </id_info>
  <brief_title>A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country
      study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed to
      compare the achievement of minimal disease activity (MDA) between subjects randomized to
      either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the
      highest recommended or tolerable dose; Part 2 is to evaluate the maintenance or achievement
      of MDA on four different treatment regimens using adalimumab and/or MTX, with subject
      allocation based on the initial randomized treatment and achievement of MDA in Part 1, and
      with rescue treatment option.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2016</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving minimal disease activity</measure>
    <time_frame>At week 16</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DLQI is a measure of subject's quality of life related to skin disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tender dactylitic digit count from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>Hands and feet bilaterally will be assessed for the presence/absence of dactylitis and associated tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28-CRP score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAS28 is a weighted measure of disease activity originally developed for RA, but is also used in PsA clinical trials. DAS28 includes tender and swollen joint counts, Patient's global assessment of disease activity, Patient's global assessment of arthritis and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PsAID score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>PsAID is a validated patient self-reported tool to assess the impact of PsA on the patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ACR 20/50/70 response</measure>
    <time_frame>At Week 16</time_frame>
    <description>ACR 20/50/70 response rate will be determined based on 20%, 50%, and 70% or greater improvement of Tender Joint Count and Swollen Joint Counts and greater than or equal to 3 of the 5 measures of Patient's assessment of pain, Patient's global assessment of disease activity, Physician's global assessment of disease activity, HAQ-DI, and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leeds Enthesitis Index (LEI) from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in minimal disease activity in Part 2 of the study</measure>
    <time_frame>At week 32</time_frame>
    <description>Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), Patient's assessment of pain visual analogue scale, Patient's global assessment of disease activity VAS, HAQ-DI, and tender entheseal points assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PASDAS from baseline</measure>
    <time_frame>Measured from Day 1 to week 16</time_frame>
    <description>Psoriatic Arthritis Disease Activity Score is a weighted disease activity measure developed specifically for psoriatic arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>SF-36 is a generic measure to assess patient's general health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAQ-DI score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>The HAQ-DI is a standardized measure of physical function in arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 75/90/100 response among subjects with BSA greater than or equal to 3%.</measure>
    <time_frame>At Week 16</time_frame>
    <description>Denotes greater than or equal to 75%/90%/100% improvement in PASI score. PASI provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAPSA score from baseline</measure>
    <time_frame>Measured from Day 1 to Week 16</time_frame>
    <description>DAPSA is a psoriatic arthritis disease activity measure, calculated by summing swollen and tender joint counts, Patient's assessment of pain, Patients global assessment of disease activity, and CRP.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rescue Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab and/or MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab +MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab + MTX low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX highest recommended or tolerable dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate (MTX)</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 1</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 3/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <arm_group_label>Arm 1/Part 1</arm_group_label>
    <arm_group_label>Arm 1/Part 2</arm_group_label>
    <arm_group_label>Arm 2/Part 2</arm_group_label>
    <arm_group_label>Arm 4/Part 2</arm_group_label>
    <arm_group_label>Rescue Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit
             and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria

          2. Not in MDA at the time of screening

          3. Has 3 or more tender and 3 or more swollen joints

          4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks

        Exclusion Criteria:

          1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or
             its excipients

          2. History of methotrexate intolerance/toxicity

          3. Medical conditions(s) precluding methotrexate dose increase above 15 mg

          4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of
             action biologic DMARD (bDMARD) or any systemic biologic agent in general
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheum Research /ID# 161796</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeJenue Research Associates /ID# 200093</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates /ID# 158655</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation /ID# 155178</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70836-6455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Gr /ID# 161057</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology, PC /ID# 162697</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Health Care /ID# 152088</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington LLC /ID# 152089</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res /ID# 152087</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research /ID# 162486</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center /ID# 162051</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia Research Inst /ID# 157815</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital /ID# 153144</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus Clinical Research Pty. /ID# 153145</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital /ID# 153147</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJC Health /ID# 153875</name>
      <address>
        <city>Paramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital /ID# 153146</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre /ID# 152345</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC /ID# 152344</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontsium /ID# 152658</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diag Consult Ctr 17 Sofia EOOD /ID# 152657</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Assoc /ID# 161600</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd /ID# 161601</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 151939</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital /ID# 159680</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Waterside Clinic /ID# 151938</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp /ID# 152575</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr. de Rheum de l'est du QC /ID# 151937</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Maladies Osseuses /ID# 205693</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A - CAYRE /ID# 153817</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Vicente Fundacion /Id# 171324</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatolog s.r.o. /ID# 151753</name>
      <address>
        <city>Jihlava 1</city>
        <state>Jihlava</state>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuselská poliklinika, Revmatologie /ID# 151754</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg /ID# 152229</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachpraxis fuer Rheumatologie und Osteologie /ID# 203982</name>
      <address>
        <city>Bruchhausen-Vilsen</city>
        <state>Niedersachsen</state>
        <zip>27305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein /ID# 152231</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI GmbH /ID# 152228</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburger Rheuma I /ID# 164055</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Catanzaro Magna Graecia /ID# 152013</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinic /ID# 152011</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese /ID# 152012</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 163089</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED /ID# 164047</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SANUS Szpital Specjalistyczny /ID# 151988</name>
      <address>
        <city>Stalowa Wola</city>
        <state>Podkarpackie</state>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspolnicy SJ /ID# 151987</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ramon L. Ortega-Colon, MD /ID# 152957</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC /ID# 152091</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamad Hospital /ID# 152334</name>
      <address>
        <city>Doha</city>
        <state>Ad Dawhah</state>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporac Sanitaria Parc Tauli /ID# 151759</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Germans Trias I Pujol /ID# 151760</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina S /ID# 151761</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Manises /ID# 162778</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Canarias /ID# 206489</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Viladecans /ID# 163875</name>
      <address>
        <city>Viladecans</city>
        <zip>8840</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Hosp for Rheuma /ID# 152767</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital /ID# 155195</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Area Hospital /ID# 152766</name>
      <address>
        <city>Londonderry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University /ID# 152765</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancashire Care NHS Foundation /ID# 152769</name>
      <address>
        <city>Preston</city>
        <zip>BT47 3EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Qatar</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

